Carbocysteine Modifies Circulating miR-21, IL-8, sRAGE, and fAGEs Levels in Mild Acute Exacerbated COPD Patients: A Pilot Study.
COPD
antioxidants
carbocysteine
exacerbations
inflammation
respiratory pharmacology
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
11 Feb 2022
11 Feb 2022
Historique:
received:
11
01
2022
revised:
07
02
2022
accepted:
08
02
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
27
2
2022
Statut:
epublish
Résumé
Patients with Chronic Obstructive Pulmonary Disease (COPD) periodically experience acute exacerbation (AECOPD). Carbocysteine represents a valid add on therapy in COPD by exerting antioxidant and anti-inflammatory activities. The in vivo effects of carbocysteine on inflammatory markers are not yet fully understood. The aims of this study were to assess: (i) miR-21, IL-8, soluble Receptor for Advanced Glycation End Products (sRAGE), and fluorescent Advanced Glycation End Products (fAGEs) in control subjects (
Identifiants
pubmed: 35215330
pii: ph15020218
doi: 10.3390/ph15020218
pmc: PMC8880736
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Research Council
ID : DSB.AD001
Organisme : Dompè
ID : DSB.AD001
Références
Sci Rep. 2017 Oct 9;7(1):12871
pubmed: 28993685
Exp Ther Med. 2020 Mar;19(3):1655-1664
pubmed: 32104217
Tanaffos. 2018 Jan;17(1):13-21
pubmed: 30116274
Hum Immunol. 2011 Jan;72(1):54-62
pubmed: 20888880
Thorax. 2019 Sep;74(9):898-905
pubmed: 31273049
J Allergy Clin Immunol. 2010 Sep;126(3):527-34.e1-8
pubmed: 20638110
Eur Respir J. 2012 Mar;39(3):721-9
pubmed: 21920897
Front Physiol. 2018 May 04;9:503
pubmed: 29780331
Pulm Pharmacol Ther. 2016 Apr;37:85-8
pubmed: 26970503
Cancer Med. 2020 Apr;9(8):2879-2890
pubmed: 32091667
J Cell Physiol. 2019 Dec;234(12):22183-22194
pubmed: 31054160
Metabolism. 2017 Jun;71:64-69
pubmed: 28521879
Eur Respir J. 2008 Feb;31(2):416-69
pubmed: 18238951
J Res Med Sci. 2018 Mar 27;23:27
pubmed: 29692824
Cancer Manag Res. 2020 Feb 07;12:871-879
pubmed: 32104069
Eur Respir J. 2011 Mar;37(3):516-22
pubmed: 20595148
Mol Biosyst. 2014 May;10(5):1072-81
pubmed: 24556821
J Cell Physiol. 2017 Oct;232(10):2851-2859
pubmed: 27925185
PLoS One. 2012;7(6):e38629
pubmed: 22701684
Respir Res. 2014 Feb 25;15:24
pubmed: 24564838
Front Immunol. 2015 Jan 29;6:19
pubmed: 25688245
Ann Intern Med. 1987 Feb;106(2):196-204
pubmed: 3492164
Respirology. 2016 Oct;21(7):1152-65
pubmed: 27028990
COPD. 2016;13(1):82-92
pubmed: 26451913
J Proteomics. 2018 Apr 15;177:11-20
pubmed: 29448054
Eur Respir J. 2017 Oct 12;50(4):
pubmed: 29025882
Lancet. 2008 Jun 14;371(9629):2013-8
pubmed: 18555912
Eur Rev Med Pharmacol Sci. 2019 Aug;23(15):6727-6735
pubmed: 31378916
Clin Chim Acta. 2001 Nov;313(1-2):69-75
pubmed: 11694241
Eur Respir J. 2019 May 18;53(5):
pubmed: 30846476
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Antioxidants (Basel). 2019 Mar 04;8(3):
pubmed: 30836666
Pharmacol Res. 2000 Jul;42(1):39-50
pubmed: 10860633
Eur J Pharmacol. 2004 Nov 28;505(1-3):169-75
pubmed: 15556150
Cell Stress Chaperones. 2013 Nov;18(6):733-43
pubmed: 23580157
Paediatr Respir Rev. 2017 Jun;23:40-49
pubmed: 28416135
Thorax. 2012 Mar;67(3):238-43
pubmed: 22008189
Free Radic Res. 2013 Aug;47 Suppl 1:3-27
pubmed: 23767955
J Pharmacol Sci. 2016 Apr;130(4):226-34
pubmed: 27038888
Respir Res. 2016 Apr 26;17:46
pubmed: 27117828
Lancet. 2007 Sep 1;370(9589):797-9
pubmed: 17765529
J Biol Chem. 2000 Aug 18;275(33):25781-90
pubmed: 10829018
Immunology. 2008 Jul;124(3):401-11
pubmed: 18217953
Thorax. 2015 Aug;70(8):782-91
pubmed: 25995155